Industry

Drug recall: Novartis recalled Cyclosporine oral solution

It is important to highlight that, as of now, Novartis has not received any reports of adverse events associated with this Drug recall.

The Health Master

September 13, 2023

258

Table of Contents

Last Updated on October 9, 2024 by The Health Master

Drug recall

Novartis, a leading pharmaceutical company, has initiated a voluntary nationwide drug recall of a specific lot of its Sandimmune® Oral Solution in the United States.

This action has been taken due to the identification of crystal formation in some bottles, potentially leading to incorrect dosing.

It is crucial to note that only one lot of Sandimmune® is affected, and other formulations remain unaffected by this issue.

Click for more articles on Drug Recall

Details of the Drug recall

1. Affected Product:

Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL
Packaged in 50 mL bottles

2. Intended Usage:

The product is primarily used for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants.
It may also be utilized in the treatment of chronic rejection in patients who have previously been treated with other immunosuppressive agents.

Risk Assessment

The crystallization of cyclosporine in Sandimmune Oral Solution raises concerns about the uniform distribution of the drug in the product.

This non-uniformity may lead to either under-dosing or over-dosing, both of which can have serious implications:

Under-dosing: This scenario may result in lower exposures, potentially decreasing the drug’s efficacy. Ultimately, this could lead to graft rejection and loss in transplant patients.
Over-dosing: Prolonged over-exposure may manifest as cyclosporine toxicity in the long term.

It is important to highlight that, as of now, Novartis has not received any reports of adverse events associated with this Drug recall.

Lot Information

Affected Lot Number: FX001691
Expiration Date: 12/2025
Distribution Commencement: April 2023
Distribution Area: Nationwide to wholesalers across the US

Response and Actions

In light of the recall, Novartis is taking the following steps:

Distributors are being promptly informed through recall notification letters.
Arrangements are being made for the return of the recalled lot by distributors, retailers, and consumers.
Health care providers who have prescribed this product are being notified to contact their patients.
Consumers possessing bottles from the recalled lot are advised to get in touch with their health care provider.

FDA Oversight

This drug recall is being carried out in coordination with the U.S. Food and Drug Administration to ensure patient safety and wellbeing.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Must read

Drug recall: Digoxin Tablets recalled due to label mix-up

Drug recall: Glenmark recalls this High BP drug due to quality reasons

Drug recall: Alembic, Aurobindo recall these drugs for this reason

Drug recall: Lupin Pharma recalled these Birth Control Pills

Drug recall: Sun Pharma, Alembic recall these drugs due to this reason

Drug recall: Dronabinol Capsules, Ziprasidone HCL Capsules recalled due to this reason